// App-Quantinova.ai

155 : Putative biomarkers of response to anti-PD-1 therapy in metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Khobe Chandran

Principal Investigators

  • Jan Rekowski

  • Irene Shui

  • Bora Gurel

  • Pasquale Rescigno

  • Emily Cross

  • Suzanne Carreira

  • Wei Yuan

  • Ines Figueiredo

  • Ana Ferreira

  • Mateus Crespo

  • Susana Miranda

  • Claudia Bertan

  • Veronica Gil

  • Ruth Riisnaes

  • Razvan Cristescu

  • Charles Schloss

  • Christina Yap

  • Johann S. De Bono

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Merck, Boston, MA

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • The Institute of Cancer Research, Sutton, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ

  • The Institute of Cancer Research, Sutton, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Programmed death-ligand 1

  • Granulin precursor

  • SRY-Box 2

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved